C.R. Bard Inc. (NYSE:BCR) will pay $184 million to settle most of the lawsuits against subsidiary Davol Inc.’s hernia repair products. Through late last year, more than 2,700 plaintiffs had filed suit in either federal or state courts pursuing product-liability claims for personal injuries, with most of those cases since transferred to the U.S. District […]
The XenMatrix FDA recall says the hernia and abdominal wall repair product has high levels of endotoxins. Davol is a subsidiary of C.R. Bard.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Medical device company Hologic will continue with a patent infringement case. The original lawsuit alleged that SenoRx violated Hologic's patents for its MammoSite brachytherapy balloon catheter device. The system delivers radiation to the cavity left from the removal of cancerous breast tissue during lumpectomy.
Johnson & Johnson's Cordis Corp. subsidiary, which makes the Cypher drug-eluting stent, confirmed that it will lay off some of its sales force and merge two sales operations in response to sliding Cypher sales. Also, C.R. Bard Inc. is cutting 200 jobs at a Queensbury, N.Y., plant.